Worth reading
66In focus
Scored from 1 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
7107900
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Exercise of stock acquisition rights with an exercise price adjustment clause
発行・処分する株式数
Shares delivered during the month: 7,107,900 new shares and 0 treasury shares transferred
発行済株式総数
Shares delivered during the month: 7,107,900; exercise ratio subject to exercise restrictions relative to the 398,835,550 listed shares as of the payment date for the issuance: 1.78%
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
Exercise price in October 2026: ¥26–¥35. Details of the adjustment clause are Not disclosed in this document
Number of Stock Acquisition Rights
Total number issued: Not disclosed; unexercised at the end of the month preceding the month covered: 732,720 rights; exercised during the month covered: 71,079 rights; unexercised at the end of the month covered: 661,641 rights
Procedures under the Corporate Code of Conduct
Describes compliance with exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments and Other Matters
Most recent equity financing
Issued on 31 August 2026: Series 47 stock acquisition rights with an exercise price adjustment clause and Series 48 stock acquisition rights. Amount: Not disclosed
| Item | Details |
|---|---|
| Type of issuance or disposal | Exercise of stock acquisition rights with an exercise price adjustment clause |
| Number of shares to be issued or disposed of | Shares delivered during the month: 7,107,900 new shares and 0 treasury shares transferred |
| Dilution Rate | Shares delivered during the month: 7,107,900; exercise ratio subject to exercise restrictions relative to the 398,835,550 listed shares as of the payment date for the issuance: 1.78% |
| Total number of issued shares | At the end of the month preceding the month covered: 405,197,250 shares → At the end of the month covered: Not disclosed |
| Exercise price | Exercise price in October 2026: ¥26–¥35. Details of the adjustment clause are Not disclosed in this document |
| Number of Stock Acquisition Rights | Total number issued: Not disclosed; unexercised at the end of the month preceding the month covered: 732,720 rights; exercised during the month covered: 71,079 rights; unexercised at the end of the month covered: 661,641 rights |
| Procedures under the Corporate Code of Conduct | Describes compliance with exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments and Other Matters |
| Most recent equity financing | Issued on 31 August 2026: Series 47 stock acquisition rights with an exercise price adjustment clause and Series 48 stock acquisition rights. Amount: Not disclosed |
Items this document does not state (20)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the monthly exercise status in October 2026 of the Series 47 stock acquisition rights with an exercise price adjustment clause and the Series 48 stock acquisition rights.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.